Pfizer (PFE) Tops Q1 EPS by 12c; Boosts FY16 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Pfizer (PFE) Target Increases at BMO Capital Following a Good Quarter
May 4, 2016 6:59 AM EDTBMO Capital analyst, Alex Arfaei, raised his PT on Pfizer (NYSE: PFE) to $40 (from $39) but admitted that much of the top-line beat was driven by more selling days in 1Q16 vs. 1Q15. Pfizers major growth drivers (e.g., Prevnar, Ibrance, Xeljanz, and Eliquis) all... More
